



## Advances in Cancer Cachexia

Guest Editors:

**Dr. Sander S. Rensen**

Department of Surgery,  
Maastricht University Medical  
Centre, Maastricht, The  
Netherlands

**Prof. Dr. Steven W. M. Olde  
Damink**

Departments of Surgery, NUTRIM  
School of Nutrition and  
Translational Research in  
Metabolism, Maastricht  
University, P.O. Box 616, 6200 MD  
Maastricht, The Netherlands

**Dr. David P.J. Van Dijk**

Department of Surgery,  
Maastricht University Medical  
Centre, Maastricht, The  
Netherlands

Deadline for manuscript  
submissions:

**closed (31 January 2024)**

### Message from the Guest Editors

In this Special Issue of *Cancers*, we aim to publish a collection of manuscripts that further our understanding of cancer cachexia and provide novel approaches of assessing cachexia severity, thereby advancing our insights into the factors that play a role in its development and enabling clinical trials with better cachexia phenotyping. In particular, we are looking for papers that describe:

- Development of novel translational models of cancer cachexia (e.g., organoids or new mouse models with slower cachexia progression);
- The role of inflammation and immune cell activation in cancer cachexia;
- The role of the liver and of insulin resistance in cancer cachexia;
- Myosteatosis and other body composition changes in patients with cancer cachexia;
- Artificial intelligence-based approaches to body composition analysis;
- Use of wearables to assess cachexia severity;
- Relationship between body composition and immunotherapy outcomes;
- Prehabilitation approaches to improve therapeutic outcome of cachectic patients.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)